Endometrial Markers and Response of Endometriosis Patients to Prolonged GnRH Agonist Prior to IVF
Completed · Phase 4
Conditions studied: Endometriosis, Infertility
In brief
This prospective randomized trial evaluates whether one can predict which infertile women with endometriosis who are candidates for in vitro fertilization will benefit from prolonged therapy with a GnRH agonist by the determination of the absence of endometrial expression of the integrin, alpha v, beta 3 vitronectin. This is a prospective randomized trial in which all patients will undergo endometrial biopsy prior to initiation of ovarian stimulation for in vitro fertilization and then undergo randomization to a three month course of a depot preparation of the GnRH agonist leuprolide acetate in depot suspension prior to ovarian stimulation or standard therapy. prio
Key facts
- Study ID
- NCT00621179
- Run by
- Colorado Center for Reproductive Medicine
- People needed
- 37
- Starts
- 2003-03-01
- Expected to finish
- 2010-01-01
- Last updated by the study team
- 2021-08-10
Who can join
Age: 21 and older, up to 42. Sex: female. Healthy volunteers: not accepted.
You may qualify if…
- Infertility
- Surgical diagnosis of endometriosis
- Normal ovarian reserve testing
- Regular menses
You may not qualify if…
- Irregular menses
- Undiagnosed abnormal uterine bleeding
- Pregnancy
- Prior adverse reaction to any GnRH agonist
- Ovarian cystic or solid mass > 3cm in mean diameter at study entry
- Use of a depot preparation of a GnRh agonist or any hormonal therapy for endometriosis within 6 months of study entry
- Current hepatic, renal, hematologic or psychiatric disorder
Where it is running
- Colorado Center for Reproductive Medicine — Lone Tree, Colorado, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.